Deep vein thrombosis landmark trials in prevention

Deep Vein Thrombosis Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Causes
Differentiating Deep vein thrombosis from other Diseases
Epidemiology and Demographics
Risk Factors
Triggers
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Approach
Assessment of Clinical Probability and Risk Scores
Assessment of Probability of Subsequent VTE and Risk Scores
History and Symptoms
Physical Examination
Laboratory Findings
Ultrasound
Venography
CT
MRI
Other Imaging Findings
Treatment
Treatment Approach
Medical Therapy
IVC Filter
Invasive Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Special Scenario
Upper extremity DVT
Recurrence
Pregnancy
Trials
Landmark Trials
Case Studies
Case #1
Deep vein thrombosis landmark trials in prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Deep vein thrombosis landmark trials in prevention
CDC on Deep vein thrombosis landmark trials in prevention
Deep vein thrombosis landmark trials in prevention in the news
Blogs on Deep vein thrombosis landmark trials in prevention
Directions to Hospitals Treating Deep vein thrombosis
Risk calculators and risk factors for Deep vein thrombosis landmark trials in prevention

Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Justine Cadet

Overview

Randomized trials have compared the efficacy and safety of antithrombins and anticoagulants in the prevention of deep vein thrombosis in the setting of surgical procedures and in the context of hospitalization for a medical illness.